Valérie Cosson

999 total citations
25 papers, 725 citations indexed

About

Valérie Cosson is a scholar working on Epidemiology, Oncology and Statistics and Probability. According to data from OpenAlex, Valérie Cosson has authored 25 papers receiving a total of 725 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Epidemiology, 5 papers in Oncology and 5 papers in Statistics and Probability. Recurrent topics in Valérie Cosson's work include Statistical Methods in Clinical Trials (5 papers), Influenza Virus Research Studies (3 papers) and Retinal Diseases and Treatments (3 papers). Valérie Cosson is often cited by papers focused on Statistical Methods in Clinical Trials (5 papers), Influenza Virus Research Studies (3 papers) and Retinal Diseases and Treatments (3 papers). Valérie Cosson collaborates with scholars based in Switzerland, China and France. Valérie Cosson's co-authors include Eliane Fuseau, Vivian Ng, Michaela Lehle, Bert L. Lum, S. Y. Amy Cheung, Lutz Harnisch, Thomas Kerbusch, Bengt Hamrén, Alexander Staab and Rolf Burghaus and has published in prestigious journals such as Journal of Clinical Oncology, Antimicrobial Agents and Chemotherapy and Clinical Pharmacology & Therapeutics.

In The Last Decade

Valérie Cosson

24 papers receiving 705 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Valérie Cosson Switzerland	12	157	154	121	108	97	25	725
Janet R. Wade United States	19	191 1.2×	116 0.8×	193 1.6×	156 1.4×	54 0.6×	37	1.0k
Shashi Amur United States	17	106 0.7×	221 1.4×	84 0.7×	78 0.7×	37 0.4×	25	999
Chuanpu Hu United States	20	81 0.5×	160 1.0×	252 2.1×	214 2.0×	223 2.3×	58	1.4k
Mark Sale United States	18	226 1.4×	257 1.7×	142 1.2×	63 0.6×	31 0.3×	42	1.1k
Marylore Chenel France	17	225 1.4×	218 1.4×	186 1.5×	54 0.5×	68 0.7×	52	975
Justin Wilkins United States	17	201 1.3×	129 0.8×	79 0.7×	193 1.8×	44 0.5×	50	925
Holly Kimko United States	14	94 0.6×	95 0.6×	70 0.6×	144 1.3×	31 0.3×	38	587
Kourosh Parivar United States	9	179 1.1×	133 0.9×	165 1.4×	30 0.3×	111 1.1×	21	649
Justin Earp United States	17	151 1.0×	231 1.5×	124 1.0×	35 0.3×	107 1.1×	36	829
Ekaterina Gibiansky United States	19	267 1.7×	361 2.3×	100 0.8×	114 1.1×	343 3.5×	42	1.3k

Countries citing papers authored by Valérie Cosson

Since Specialization

Citations

This map shows the geographic impact of Valérie Cosson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Valérie Cosson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Valérie Cosson more than expected).

Fields of papers citing papers by Valérie Cosson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Valérie Cosson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Valérie Cosson. The network helps show where Valérie Cosson may publish in the future.

Co-authorship network of co-authors of Valérie Cosson

This figure shows the co-authorship network connecting the top 25 collaborators of Valérie Cosson. A scholar is included among the top collaborators of Valérie Cosson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Valérie Cosson. Valérie Cosson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cosson, Valérie, Rong Fu, Austin Kulasekararaj, et al.. (2025). Pharmacokinetic characterization and exposure–response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria. British Journal of Clinical Pharmacology. 91(5). 1479–1490.

Avery, Robert L., Chui Ming Gemmy Cheung, Karl G. Csaky, et al.. (2024). Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema. Translational Vision Science & Technology. 13(11). 13–13. 4 indexed citations

Cosson, Valérie, et al.. (2024). Simulation‐based evaluation of the Pharmpy Automatic Model Development tool for population pharmacokinetic modeling in early clinical drug development. CPT Pharmacometrics & Systems Pharmacology. 13(10). 1707–1721. 2 indexed citations

Retout, Sylvie, et al.. (2022). A Pharmacokinetics–Time to Alleviation of Symptoms Model to Support Extrapolation of Baloxavir Marboxil Clinical Efficacy in Different Ethnic Groups with Influenza A or B. Clinical Pharmacology & Therapeutics. 112(2). 372–381. 1 indexed citations

Liu, Yanmei, Sylvie Retout, Vincent Duval, et al.. (2022). Pharmacokinetics, safety, and simulated efficacy of an influenza treatment, baloxavir marboxil, in Chinese individuals. Clinical and Translational Science. 15(5). 1196–1203. 11 indexed citations

Schwab, Dietmar, et al.. (2021). A Baseline Score to Predict Response to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration. Translational Vision Science & Technology. 10(6). 11–11. 6 indexed citations

Cosson, Valérie, et al.. (2021). How Semiphysiological Population Pharmacokinetic Modeling Incorporating Active Hepatic Uptake Supports Phase II Dose Selection of RO7049389, A Novel Anti–Hepatitis B Virus Drug. Clinical Pharmacology & Therapeutics. 109(4). 1081–1091. 8 indexed citations

Yuen, Man‐Fung, Xue Zhou, Edward Gane, et al.. (2021). Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial. The Lancet. Gastroenterology & hepatology. 6(9). 723–732. 43 indexed citations

Wang, Ka, Tilman Schlothauer, Angelika Lahr, et al.. (2017). An apparent clinical pharmacokinetic drug–drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism. Cancer Chemotherapy and Pharmacology. 79(4). 661–671. 8 indexed citations

10.

Burghaus, Rolf, Valérie Cosson, S. Y. Amy Cheung, et al.. (2015). Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation. CPT Pharmacometrics & Systems Pharmacology. 5(3). 93–122. 257 indexed citations

11.

Cosson, Valérie, Vivian Ng, Michaela Lehle, & Bert L. Lum. (2014). Population pharmacokinetics and exposure–response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. Cancer Chemotherapy and Pharmacology. 73(4). 737–747. 87 indexed citations

12.

Gibiansky, Leonid, et al.. (2014). Methods to detect non-compliance and reduce its impact on population PK parameter estimates. Journal of Pharmacokinetics and Pharmacodynamics. 41(3). 279–289. 7 indexed citations

13.

Kjellsson, Maria C., Valérie Cosson, Norman A. Mazer, Nicolas Frey, & Mats O. Karlsson. (2013). A Model‐Based Approach to Predict Longitudinal HbA1c, Using Early Phase Glucose Data From Type 2 Diabetes Mellitus Patients After Anti‐Diabetic Treatment. The Journal of Clinical Pharmacology. 53(6). 589–600. 18 indexed citations

14.

Logan, Jean, Gene‐Jack Wang, Frank Telang, et al.. (2007). Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress. Nuclear Medicine and Biology. 34(6). 667–679. 65 indexed citations

15.

Fuseau, Eliane, et al.. (2003). Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients. European Journal of Clinical Pharmacology. 59(11). 783–790. 33 indexed citations

16.

Cosson, Valérie & Eliane Fuseau. (1999). Mixed Effect Modeling of Sumatriptan Pharmacokinetics During Drug Development: II. From Healthy Subjects to Phase 2 Dose Ranging in Patients. Journal of Pharmacokinetics and Biopharmaceutics. 27(2). 149–171. 25 indexed citations

17.

Cosson, Valérie, Eliane Fuseau, Constantin Efthymiopoulos, & Alan Bye. (1997). Mixed Effect Modeling of Sumatriptan Pharmacokinetics During Drug Development. I: Interspecies Allometric Scaling. Journal of Pharmacokinetics and Biopharmaceutics. 25(2). 149–167. 30 indexed citations

18.

Bruno, René, Valérie Cosson, J. Vergniol, et al.. (1995). Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. Cancer Chemotherapy and Pharmacology. 37(1-2). 47–54. 49 indexed citations

19.

Bruno, René, Bruno Lacarelle, Valérie Cosson, et al.. (1992). Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: Application to pefloxacin in intensive care unit patients. Journal of Pharmacokinetics and Biopharmaceutics. 20(6). 653–669. 25 indexed citations

20.

Urtizberea, M., A. Sabouraud, Olivier Chappey, et al.. (1991). Pharmacokinetics of Total and Free Digoxin and Fab Fragments in 5 Intoxicated Patients after Administration of Specific Anti-Digoxin Fab Fragments. Archives of toxicology. Supplement. 14. 132–135. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact